Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01114282 · ClinicalTrials.gov registry record · Phase 1
Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM
A Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT01114282: Completed Phase 1 study, sponsored by Stanford University.
NCT01114282 is a Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 11 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01114282, a Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of this trial is to find out the maximum tolerated dose (MTD) of bortezomib (VELCADE) in combination with pralatrexate in patients with previously treated multiple myeloma, AL amyloid and Waldenstroem's macroglobulinemia.
Interventions
- DRUG Pralatrexate
- DRUG velcade
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2010-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01114282
The ClinicalTrials.gov registry entry for NCT01114282 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pralatrexate is the first listed.
NCT01114282 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01114282 about?
NCT01114282 is a clinical study titled "Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM". The purpose of this trial is to find out the maximum tolerated dose (MTD) of bortezomib (VELCADE) in combination with pralatrexate in patients with previously treated multiple myeloma, AL amyloid and Waldenstroem's macroglobulinemia.
What is the current status of trial NCT01114282?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2010-08.
What interventions are being tested in trial NCT01114282?
The interventions under investigation include: Pralatrexate (DRUG), velcade (DRUG).
Who is sponsoring clinical trial NCT01114282?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.